secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuBase Therapeutics, Inc. (—)
CIK:        0001173281
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001104659-24-056957
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuBase Therapeutics receives Nasdaq delisting notice; trading to be suspended May 13 amid planned dissolution
--------------------------------------------------------------------------------

- Nasdaq notified NeuBase on May 2, 2024 that it failed to regain compliance with $1.00 minimum bid price requirement.
- Company does not intend to appeal; trading suspension expected at open on May 13, 2024, followed by Form 25-NSE filing.
- Board previously approved liquidation and dissolution, subject to stockholder vote at special meeting on May 13, 2024.
- In light of planned dissolution, company will not seek an appeal of the delisting determination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173281/000110465924056957/0001104659-24-056957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173281/000110465924056957/tm2413464d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-056957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer